Price-: 167 Rs
Key Aspects-: 5y cagr profit growth 37% | Significant capex + expansion into Oncology products.
Marketcap-: Rs 286 crs
This Company has shown strong headwinds for future growth. Company is engaged in mfg & marketing of premium medicines with a product portfolio of 155 formulations in more than 23 therapeutic areas. However there does exits some key risks, do read full report for more information and share this with maximum people because we are sure very few people might have heard about this company.